Crispr Therapeutics AG Form 4 insider transactions

Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG, reported a transaction in 750 shares of common stock on August 7, 2026.

Director Simeon George was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Director Ali Behbahani was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Director Maria Fardis was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Director Harold Edward Fleming was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Director John Greene was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Director Katherine A. High was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Director Sandesh Mahatme was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Director Morrison Briggs was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Director Christian Rommel was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Director Douglas A. Treco was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

General Counsel and Secretary James R. Kasinger was granted 17,000 restricted stock units by CRISPR Therapeutics AG.

Chief Medical Officer Naimish Patel was granted 22,000 restricted stock units by CRISPR Therapeutics.

CRISPR Therapeutics CFO Raju Prasad was granted 19,500 restricted stock units vesting in November 2028.

Chief Medical Officer Naimish Patel acquired 10,000 shares via RSU vesting and sold 3,786 shares to cover tax obligations.

CRISPR Therapeutics General Counsel James R. Kasinger reported new stock option and RSU grants, along with a tax-related sale of common shares.

CRISPR Therapeutics CEO Samarth Kulkarni reported the acquisition of common shares from RSU vesting, a tax-related sale, and new grants of stock options and restricted stock units.

CRISPR Therapeutics' CFO, Raju Prasad, disclosed new stock option and restricted stock unit grants, alongside a non-discretionary sale of shares to cover tax obligations.

CRISPR Therapeutics' Chief Medical Officer, Naimish Patel, received significant equity awards including stock options and restricted stock units.

CRISPR Therapeutics' Chief Medical Officer, Naimish Patel, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

CRISPR Therapeutics CFO Raju Prasad reported the vesting of restricted stock units, subsequent sales to cover tax obligations, and a gift of common shares.

CRISPR Therapeutics General Counsel James R. Kasinger sold 3,450 common shares to cover tax obligations following the vesting of restricted stock units.

CRISPR Therapeutics CEO Samarth Kulkarni reported the vesting of restricted stock units and a subsequent non-discretionary sale of shares to cover tax obligations.

CRISPR Therapeutics' General Counsel, James R. Kasinger, acquired 5,500 common shares through RSU vesting and subsequently sold 2,800 shares to cover tax obligations.

CRISPR Therapeutics CEO Samarth Kulkarni reported the vesting of 19,250 restricted stock units and a subsequent non-discretionary sale of 9,798 shares to cover tax obligations.

CRISPR Therapeutics' Chief Medical Officer, Naimish Patel, has agreed to repay $4,493.84 in short-swing profits from recent share transactions.

CRISPR Therapeutics' CFO, Raju Prasad, exercised stock options and subsequently sold a portion of the acquired common shares under a pre-arranged trading plan.

CRISPR Therapeutics CEO Samarth Kulkarni sold a total of 90,000 common shares in pre-planned transactions in January 2026.

CRISPR Therapeutics' Chief Financial Officer, Raju Prasad, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

CRISPR Therapeutics AG's Chief Financial Officer, Raju Prasad, reported the sale of 10,000 common shares for approximately $559,584.80 through a pre-arranged 10b5-1 trading plan.